Altimmune, Inc.
NASDAQ:ALT
Overview | Financials
 | Company Name | Altimmune, Inc. | 
| Symbol | ALT | 
| Currency | USD | 
| Price | 3.71 | 
| Market Cap    |  327,434,583 | 
| Dividend Yield    |  0% | 
| 52-week-range | 2.9 - 11.16 | 
| Industry | Biotechnology | 
| Sector | Healthcare | 
| CEO | Dr. Vipin K. Garg Ph.D. | 
| Website | https://altimmune.com | 
An error occurred while fetching data.
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is 
 Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD








